News FDA approves GSK's Blenrep for advanced multiple myeloma The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease.
News CHMP gives nod to GSK’s BCMA drug Blenrep for myeloma GlaxoSmithKline is closing in on EU approval for its first-in-class BCMA-targeting drug Blenrep, after getting a green light from the EMA’s human medicines committee.